Fasikl Secures $26.5 Million in Series B Venture Capital Investment

(MINNEAPOLIS, Minn.) September 10, 2025 – Fasikl has closed a $26.5 million Series B funding round to accelerate the development and commercialization of next-generation AI therapeutics. The proceeds will support R&D efforts aimed at enhancing efficacy, expanding clinical applications, and improving user experience for upcoming AI therapeutic products targeting essential tremor and other neurological disorders. Funds will also be directed toward clinical trials and commercial preparations for the Felix launch.